EA201400273A1 - Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин - Google Patents

Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин

Info

Publication number
EA201400273A1
EA201400273A1 EA201400273A EA201400273A EA201400273A1 EA 201400273 A1 EA201400273 A1 EA 201400273A1 EA 201400273 A EA201400273 A EA 201400273A EA 201400273 A EA201400273 A EA 201400273A EA 201400273 A1 EA201400273 A1 EA 201400273A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reducing
immunoglobulin
plasma
received
composition containing
Prior art date
Application number
EA201400273A
Other languages
English (en)
Other versions
EA030251B1 (ru
Inventor
Вольфганг Тешнер
Харальд Арно Буттервек
Бернхард Кельбль
Лючия Хофбауэр
Ханс-Петер Шварц
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А. filed Critical Бакстер Интернэшнл Инк.
Publication of EA201400273A1 publication Critical patent/EA201400273A1/ru
Publication of EA030251B1 publication Critical patent/EA030251B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предлагаются способы снижения содержания амидолитической активности и активности против комплемента (АПК) в композиции, содержащей иммуноглобулин, путем применения катионообменной хроматографии. В конкретном варианте изобретения предлагаются способы уменьшения содержания фактора XI, и/или фактора Хiа, и/или АПК в композиции, содержащей иммуноглобулин, путем сбора ранней фракции элюата катионообменной колонки. В настоящем изобретении также предлагается композиция, содержащая иммуноглобулин, которая содержит сниженные уровни амидолитической активности фактора XI, и/или фактора Хiа, и/или АПК.
EA201400273A 2011-08-26 2012-08-27 Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин EA030251B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527974P 2011-08-26 2011-08-26
PCT/US2012/052567 WO2013033042A1 (en) 2011-08-26 2012-08-27 Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition

Publications (2)

Publication Number Publication Date
EA201400273A1 true EA201400273A1 (ru) 2014-08-29
EA030251B1 EA030251B1 (ru) 2018-07-31

Family

ID=46970397

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400273A EA030251B1 (ru) 2011-08-26 2012-08-27 Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин

Country Status (20)

Country Link
US (1) US9403899B2 (ru)
EP (1) EP2748193B1 (ru)
JP (1) JP6165143B2 (ru)
KR (1) KR101949553B1 (ru)
CN (1) CN103874708B (ru)
AR (1) AR087953A1 (ru)
AU (1) AU2012300220C1 (ru)
BR (1) BR112014004445B1 (ru)
CA (1) CA2846599A1 (ru)
CL (1) CL2014000480A1 (ru)
CO (1) CO6920256A2 (ru)
EA (1) EA030251B1 (ru)
ES (1) ES2624485T3 (ru)
HK (1) HK1199267A1 (ru)
IL (1) IL231083B (ru)
MX (1) MX349005B (ru)
MY (1) MY165164A (ru)
SG (1) SG11201400233TA (ru)
TW (1) TWI610937B (ru)
WO (1) WO2013033042A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2015137530A1 (ko) * 2014-03-11 2015-09-17 주식회사 녹십자홀딩스 면역글로불린의 정제방법
CN106414476B (zh) * 2014-03-11 2019-12-31 株式会社绿十字控股 用于纯化免疫球蛋白的方法
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
WO2018229760A1 (en) * 2017-06-12 2018-12-20 Kamada Ltd. Immunoglobulin compositions and process for obtaining the same
WO2023215722A1 (en) * 2022-05-02 2023-11-09 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (ru) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
JPS5598117A (en) * 1979-01-17 1980-07-25 Chemo Sero Therapeut Res Inst Purification of gamma-globulin derivative
US4639513A (en) 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
ATE59144T1 (de) 1984-07-07 1991-01-15 Armour Pharma Gmbh Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
DE3640513A1 (de) 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE59309332D1 (de) 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
MY157239A (en) * 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof

Also Published As

Publication number Publication date
KR20140062088A (ko) 2014-05-22
JP2014525417A (ja) 2014-09-29
EP2748193B1 (en) 2017-02-01
AU2012300220C1 (en) 2016-11-10
AU2012300220B2 (en) 2015-09-10
BR112014004445A2 (pt) 2017-03-28
BR112014004445B1 (pt) 2022-11-22
CO6920256A2 (es) 2014-04-10
US20130058961A1 (en) 2013-03-07
MX2014002204A (es) 2014-06-11
AU2012300220A1 (en) 2013-05-02
SG11201400233TA (en) 2014-08-28
HK1199267A1 (en) 2015-06-26
MY165164A (en) 2018-02-28
IL231083B (en) 2019-06-30
EA030251B1 (ru) 2018-07-31
EP2748193A1 (en) 2014-07-02
TW201326192A (zh) 2013-07-01
CA2846599A1 (en) 2013-03-07
IL231083A0 (en) 2014-03-31
MX349005B (es) 2017-07-06
CN103874708B (zh) 2018-07-10
KR101949553B1 (ko) 2019-02-18
JP6165143B2 (ja) 2017-07-19
WO2013033042A1 (en) 2013-03-07
ES2624485T3 (es) 2017-07-14
AR087953A1 (es) 2014-04-30
CL2014000480A1 (es) 2014-10-03
CN103874708A (zh) 2014-06-18
TWI610937B (zh) 2018-01-11
US9403899B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
IN2013MU02145A (ru)
AU2017286676A8 (en) Purification of multispecific antibodies
NZ741129A (en) Anti-pd1 antibodies and methods of use
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
MX2018013128A (es) Molecula de union al antigeno para promover la perdia de antigeno a traves de fc gamma riib.
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201491385A1 (ru) Соединения, ингибирующие металлоферменты
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201490195A1 (ru) Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
MX347020B (es) Anticuerpo contra el csf-1r.
BR112021023345A2 (pt) Imunotolerância com alvo em madcam
IN2014DN08481A (ru)
WO2012013682A3 (en) Protein purification
MX2014013149A (es) Anticuerpos anti-il-23p19.
MX2023008870A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
EA201691834A1 (ru) Новый способ очистки гонадотропина
MX368107B (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
MX2013003716A (es) Metodo para purificacion de factor h de complemento.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
EA201690264A1 (ru) Способ очистки pth
WO2013071127A8 (en) Monoclonal antibodies against serotransferrin antigens, and uses therefor
WO2012066569A8 (en) A novel process for the purification of tissue plasminogen activator

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment